Capital markets·October 23, 2026 at 5:35 PM EDT·1 source
Novo-Backed Windward Bio Files for US IPO to Fund Antibody Drugs
Capital markets
What happened
- Windward Bio Group AG filed for a US initial public offering.
- The company plans to use the proceeds to fund trials of antibody drugs for serious respiratory and skin diseases.
Why it matters
The filing may be relevant to ECM professionals tracking biotech IPO activity and funding for clinical-stage drug developers.
Deal terms
ipo
Windward Bio Group AG
Value
—
Investors
Novo
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Who is involved
Novo-Backed Windward Bio Files for US IPO to Fund Antibody DrugsWindward Bio Group AGtargetNovo
CompanyInvestor
Sources (1)
- BloombergYesterdayNovo-Backed Windward Bio Files for US IPO to Fund Antibody Drugs
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.